VOLUME 40 , ISSUE 1ENG ( Feb-2012, 2012 ) > List of Articles
Jose M. Ruiz-Moreno, Javier A. Montero, Pedro Amat-Peral, Francisco L. Lugo
Citation Information : Ruiz-Moreno JM, Montero JA, Amat-Peral P, Lugo FL. Bevacizumab and Cataract Surgery in AMD. 2012; 40 (1ENG):20-24.
DOI: 10.5005/hoo-10101-40105
Published Online: 21-09-2020
Copyright Statement: Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.
Introduction: Inflammatory mediators such as those released by surgery may induce choroidal neovasculari- zation (CNV) re-activation. We report the use of intravitreal bevacizumab associated with cataract surgery to prevent CNV re-activation in patients with previously treated CNV associated with Age Related Macular Degeneration (AMD). Patients and Methods: Interventional case series of fourteen eyes from 14 patients presenting cataracts who had been previously treated for wet AMD. The patients underwent clear cornea phacoemulsification with intraocular lens implantation. An intravitreal injection of 1.25 mg (0.05 ml) bevacizumab was performed by the end of the procedure. The historical data of nine patients previously treated for wet AMD who had undergone cataract surgery at our hospital were used as control group. The results were evaluated in terms of visual acuity improvement and reactivation of CNV as determined by the appearance of fluid in optical coherence tomography (OCT). Results: Best corrected visual acuity (BCVA) significantly improved after surgery (p=0.000, Student t test for paired data). Mean follow-up after cataract surgery was 13.5 months (SD 6.5, range 6 to 25 months). CNV re-activation or new CNV lesions were not observed in any case during follow-up in the treated group. CNV re- activation was observed in two cases at 4 and 6 months after cataract surgery in the control group. Conclusion: Intravitreal bevacizumab injected immediately after cataract surgery may prevent CNV re-activation in patients with previously treated CNV secondary to AMD.